Bone disease in thalassemia

Rivista Italiana di Medicina dell'Adolescenza

Volumn 3, Issue 3, 2005, Pages 49-55

  Soliman, Ashraf T ^a  

^a HAMAD MEDICAL CORPORATION   (Qatar)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CHORIONIC GONADOTROPIN; DEFEROXAMINE; ESTROGEN; GROWTH HORMONE; IRON; OSTEOCALCIN; PAMIDRONIC ACID; SEX HORMONE; SOMATOMEDIN C RECEPTOR; STRONTIUM RANELATE; TESTOSTERONE; VITAMIN D; ZOLEDRONIC ACID;

ARTICLE; BONE DENSITY; BONE DISEASE; BONE DYSPLASIA; BONE MASS; BONE MINERALIZATION; CALCIUM INTAKE; CALORIC INTAKE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; EARLY DIAGNOSIS; FEMUR NECK; FRACTURE; GROWTH DISORDER; HISTOPHOTOMETRY; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; IRON CHELATION; IRON OVERLOAD; KINESIOTHERAPY; LUMBAR SPINE; MORBIDITY; NERVE COMPRESSION; NUTRITIONAL DEFICIENCY; OSSIFICATION; OSTEOID; OSTEOLYSIS; OSTEOMALACIA; OSTEOPENIA; OSTEOPOROSIS; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SKELETON MALFORMATION; SPINE MALFORMATION; THALASSEMIA;

EID: 30744478925     PISSN: None     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Pootrakul P, Hungsprenges S, Fucharoen S, Baylink D et al. Relation between erythropoiesis and bone metabolism in thalassemia. N Engl J Med 1981; 304: 1470.
2. Korovessis P, Papanastasiou D, Tiniakou M, Beratis NG. Incidence of scoliosis in β-thalassemia and follow-up evaluation. Spine 1996; 21: 1798.
3. Olivieri NF, Koren G, Harris J, Khattak S et al. Growth failure and bony changes induced by deferoxamine. Am J Ped Hematol Oncol 1992; 14: 48.
4. Orvieto, R, Leichter I, Rachmilewitz EA, Margulies JY. Bone density, mineral content and cortical index in patients with thalassemia major and the correlation to their bone fractures, blood transfusions and treatment with desferrioxamine. Calcif Tissue Int 1992; 50: 397.
5. Pearson HA. The evaluation of thalassemia intermedia. In Proceedings of thalassemia intermedia: A region I conference. The Genetic Resource: Special Issue 1997; 11: 5.
6. Singer ST, Vichinsky A. Bone disease in beta-thalassemia. Lancet 1999; 354: 881.
7. Caffey J. Cooley's anemia: a review of the roentgenographic findings in the skeleton. AJR 1957; 78: 381.
8. Korsten J, Grossman H, Winchester PH. Extramedullary hematopoiesis in patients with thalassemia anemia. Radiology 1970; 95: 257.
9. Lawson JP, Ablow RC, Pearson HA. Calvarial and phalangeal vascular impressions in thalassemia. AJR 1984; 143: 641.
10. Lawson JP, Ablow RC, Pearson HA. The ribs in thalassemia. II. The pathogenesis of the changes. Radiolog 1981; 140: 673.
11. Long JA Jr, Doppman JL, Nienhus AW. Computed tomographic analysis of beta-thalassemic syndromes with hemochromatosis: pathologic findings with clinical and laboratory correlations. J Comput Assist Tomogr 1980; 4: 159.
12. Rodda CP, Reid FD, Johnson S, Doery J et al. Short stature in homozygous β-thalassaemia is due to disproportionate truncal shortening. Clin Endocrinol 1995; 42: 587.
13. De Virgilis ST, Congia M, Frau F et al. Deferoxamine induced growth retardation in patients with thalassemia major. J Pediatr 1988; 113: 661.
14. Consensus Development Conference. Diagnosis, prophylaxis and treatment of osteoporosis. Peck WA, Chairman. Am J Med 1993; 94: 646.
15. Lindsay R. Prevention and treatment of osteoporosis. Lancet 1993; 341: 801.
16. Mahachoklertwattana P, Sirikulchayanonta V, Chuansumrit A, Karnsombat P et al. Bone histomorphometry in children and adolescents with β-Thalassemia disease: iron-associated focal osteomalacia. J Clin Endocrinol Metab 2003; 88: 3966.
17. Wonke B, Jensen C, Hanslip JJ, Prescott E, Lalloz M et al. Genetic and acquired predisposing factors and treatment of osteoporosis in thalassaemia major. J Pediatr Endocrinol Metab 1998; 11 (Suppl 3):795.
18. De Sanctis V, Savarino L, Stea S, Cervellati M et al. Microstructural analysis of severe bone lesions in seven thalassemic patients treated with deferoxamine. Calcif Tissue Int 2000; 67:128.
19. Soliman AT, Banna NE, Fattah MA, EI Zalabani MM, Ansari BM. Bone mineral density in prepubertal children with β-thalassemia: correlation with growth and hormonal data. Metabolism 1998; 47: 541.
20. Anapliotou ML, Kastanias IT, Psara P, Evangelou EA et al. The contribution of hypogonadism to the development of osteoporosis in thalassemia major: new therapeutic approaches. Clin Endocrinol (Oxf) 1995; 42:279.
21. Heaney RP. Nutritional factors in osteoporosis. Ann Rev Nutr 1993; 13: 287.
22. Low LCK, Postel-Vinay MC, Kwan EYM, Cheung PT. Serum growth hormone (GH) binding protein, IGF-I and IGFBP-3 in patients with β-thalassemia major and the effect of GH treatment. Clin Endocrinol (Oxf) 1998; 48: 641.
23. Pollak RD, Rachmilewitz E, Blumenfeld A, Idelson M et al. Bone mineral metabolism in adults with β-thalassemia major and intermedia. Br J Haematol 2000; 111: 902.
24. Soliman AT, Banna NE, Ansari BM. GH response to provocation and circulating IGF-I and IGF-binding protein-3 concentrations, the IGF-I generation test and clinical response to GH therapy in children with β-thalassaemia. Eur J Endocrinol 1998; 138: 394.
25. Korsten J, Grossman H, Winchester PH. Extramedullary hematopoiesis in patients with thalassemia anemia. Radiology 1970; 95: 257.
26. De Sanctis V. Growth and puberty and its management in thalassemia. Horm Res 2002; 58 (Supp. 1): 72.
27. Italian Working Group on Endocrine Complications in Non-Endocrine Diseases. Multicenter study on prevalence of endocrine complication in Thalassemia Major. Clin Endocrinol 1995; 42: 581.
28. Soliman AT, Zalabani MM, Ragab M, Rogol AD et al. Spontaneous and provoked gonadotrophin secretion and circulating sex-steroid concentrations and their response to human chorionic gonadotrophin in adolescent boys with thalassemaemia major -and delayed puberty. J Trop Pediatr 1999; 45: 327.
29. Riggs L. The mechanisms of estrogen regulation of bone resorption. J Clin Invest 2000; 106: 1203.
30. Aloia JF, Ostuni JA, Yeh JK, Zaino EC. Combined vitamin D parathyroid defect in thalassemia major. Arch Int Med 1982; 142: 831.
31. Moulas A, Challa A, Choliasos N, Lapatsanis PD. Vitamin D metabolites (25-hydroxyvitamin D, 24,25-dihydroxyvitamin D and 1,25-dihydroxyvitamin D) and osteocalcin in β-thalassemia. Acta Paediatr 1887; 86: 594.
32. Soliman AT, El-Matary W, Fattah MM, Nasr IS et al. The effect of high-calorie diet on nutritional parameters of children with beta halassaemia major. Clin Nutr 2004; 23: 1153.
33. Fuchs GJ, Tienboon P, Linpisarn S, Nimsakul S et al. Nutritional factors and thalassaemia major. Arch Dis Child 1996; 74: 224.
34. De Vernejoul MC, Pointillart A, Golenzer CC, Morieux C et al. Effects of iron overload on bone remodeling in pigs. Am J Pathol 1984; 116: 377.
35. De Sanctis V, Stea S, Savarino L, Scialpi V et al. Growth hormone secretion and bone histomorphometric study in thalassemic patients with acquired skeletal dysplasia secondary to desferrioxamine. J Ped Endocrinol Metab 1998; 11: 827.
36. Cappellini M, Cohen A, Eleftheriou A, Piga A et al. Endocrine Complications in Thalassaemia Major. In: Guidelines for the clinical management of thalassaemia. TIF 2000, 41.
37. Johnston CC, Miller JZ, Slemenda CW, Reister TK et al. Calcium supplementation and increases in bone mineral density in children. N Engl J Med 1992; 2, 327: 82.
38. Moulas A, Challa A, et al. Vitamin D metabolites (25-hydroxyvitamin D, 24,25-dihydroxyvitamin D and 1,25-dihydroxyvitamin D) and osteocalcin in beta-thalassemia. Acta Paed 1997; 86: 594.
39. Sartorio A, Conte G, Conti A, Masala A et al. Effects of 12 months rec-GH therapy on bone and collagen turnover and bone mineral density in GH deficient children with thalassaemia major. J Endocrinol Invest 2000; 23: 356.
40. Wang C, Tso SC, Todd D. Hypogonadotropic hypogonadism in severe beta-thalassemia: effect of chelation and pulsatile gonadotropin-releasing hormone therapy. J Clin Endocrinol Metab 1989; 68: 511.
41. Soliman AT, Nasr I, Thabet A, Rizk MM et al. Human chorionic gonadotropin therapy in adolescent boys with constitutional delayed puberty vs those with β-thalassemia major. Metabolism 2005,54:15.
42. Theodoridis C, Ladis V, Papatheodorou A et al. Growth and management of short stature in thalassemia major. J Ped Endocrinol Metab 1998; 11 (Suppl 3): 835.
43. Katz M, De Sanctis V, Vullo C, Wonke B et al. Pharmacokinetics of sex steroids in patients with β-thalassemia major. J Clin Pathol 1993; 46: 660.
44. Chern JP, Lin KH. Hypoparathyroidism in transfusion-dependent patients with beta-thalassemia. J Pediatr Hematol Oncol 2003; 25: 275.
45. Cianfarani S, Bonfanti R, Bitti MLM, Germani D et al. Growth and Insulin-Like Growth Factors (IGFs) in Children with Insulin-Dependent Diabetes Mellitus at the Onset of Disease: Evidence for Normal Growth, Age Dependency of the IGF System Alterations, and Presence of a Small (Approximately 18-Kilodalton) IGF-Binding Protein-3 Fragment in Serum. J Clin Endocrinol Metab 2000; 85: 4162.
46. Voskaridou, E, Terpos E, Spina G, Palermos J et al. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. Br J Haematol 2003; 123: 730.
47. Morabito N, Lasco A, Gaudio A, Crisafulli A, Di Pietro C et al. Bisphosphonates in the treatment of thalassemia-induced osteoporosis. Osteoporosis Int 2002; 13: 644.
48. Viereck V, Emons G, Lauck V, Frosch KH et al. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin pr0oduction by primary human osteoblasts. Bioch Bioph Res Com 2002; 291: 680.
49. Canatan D, Akar N, Arcasoy A. Effects of calcitonin therapy on osteoporosis in patients with thalassemia. Acta Haematol 1995; 93: 20.